Other Affiliated Sites
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
A-Share Information
H-Share Information
2020.08.01
独立董事提名人声明
2020.08.01
独立董事提名人声明
2020.08.01
独立董事提名人声明
2020.08.01
独立董事候选人声明
2020.08.01
第四届董事会第三十六次会议决议公告
2020.07.31
关于稳定价格行动、稳定价格期间结束及超额配售权失效的公告
2020.07.31
关于公司问询函中有关财务事项的说明
2020.07.31
关于公司问询函中有关财务事项的说明
2020.07.31
关于对深圳证券交易所2019年年报问询函回复的公告
2020.07.15
2020年半年度业绩预告
第一页
上一页
35
36
37
38
39
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.
